U.S. COMPANY FILING
AMGEN INC — Form 10-Q filed 2026-05-01
Filing text preview
Amgen's Q1 2026 revenue rose 5.8% to $8.618B, net income up 5.1% to $1.819B, diluted EPS $3.34. Product sales grew, led by Repatha and EVENITY. Declared dividend of $2.52/share. TAVNEOS faces FDA withdrawal proposal, but company intends to engage.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record